tbuckley/cabot-search huggingface dataset:
Can estimated glomerular filtration rate (eGFR) replace isotopic measurement of GFR for carboplatin dosing in stage 1 seminoma?
Authors: Scott T.C. Shepherd, Gerry Gillen, Paula Morrison, Carla Forte, Iain R. MacPherson, Patrick Mark, Jeff D. White
Journal: Journal of Clinical Oncology (2013)

2589 Background: Accurate determination of GFR is essential for correct dosing of carboplatin, the standard adjuvant therapy for stage 1 seminoma. Isotopic methods (e.g. 51Cr-EDTA) remain the gold standard for determination of GFR. However, the use of eGFR could reduce the need for such isotope studies. As novel formulae to estimate GFR such as CKD-EPI and MDRD4 have improved the assessment of renal function in non-oncological settings, we investigated their utility for carboplatin dosing. Methods: 115 patients (pts) (mean age 40.3, std dev. 10.1) who received adjuvant carboplatin for stage 1 seminoma at our institution between 2007-2012 were identified. All pts underwent 51Cr-EDTA measurement of GFR with carboplatin dose calculated using the Calvert formula, based on GFR uncorrected for body surface area (BSA). Theoretical carboplatin doses were then calculated using eGFR values obtained using the CKD-EPI and MDRD4 formulae with additional calculation to uncorrect for BSA. Creatinine clearance was calculated by Cockcroft-Gault (CG) formula. For each pt the carboplatin doses calculated by eGFR were compared with the actual dose calculated by the gold-standard method; a difference of less than 10% was considered acceptable. Results: The Table shows the percentage of pts who would have received an equivalent carboplatin dose using each eGFR formula compared to the dose calculated using 51Cr-EDTA. The CKD-EPI formula performed best with 58.9% of pts receiving within 10% of the correct dose. Pts predicted to be underdosed by CKD-EPI eGFR were more likely to be obese (BMI &gt;30) (p=0.01); there were no predictors of the 18.8% who would have received an excess dose. Conclusions: Our data support further evaluation of the CKD-EPI formula but highlight the clinically significant variances in carboplatin dosing when using non-isotopic methods of GFR estimation. [Table: see text]
IMPROVEMENT OF CHA2DS2-VASC RISK STRATIFICATION OF STROKE AND MORTALITY USING THE INTERMOUNTAIN RISK SCORE AMONG ATRIAL FIBRILLATION PATIENTS UNDERGOING CARDIAC CATHETERIZATION
Authors: Benjamin Davies Horne, T. Jared Bunch, Heidi May, Kirk Knowlton, Joseph B. Muhlestein, Kevin G. Graves, Victoria Jacobs, Donald Lappe
Journal: Journal of the American College of Cardiology (2017)
COMPARISON OF BLEEDING RATES AND CLINICAL OUTCOMES BETWEEN TICAGRELOR AND PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A PROPENSITY SCORE-MATCHED ANALYSIS
Authors: Jeong Cheon Choe, Lee Sun Hack, Jinhee Ahn, Jin Sup Park, Hye Won Lee, Jun-Hyok Oh, Jung Hyun Choi, Han Cheol Lee, Kwang Soo Cha, Taek Jong Hong
Journal: Journal of the American College of Cardiology (2017)
Prospective Evaluation of Thromboembolic Events During Chemotherapy of Childhood Acute Lymphoblastic Leukemia: Results of Randomized Trial ALL-BFM 2000.
Authors: Anja Möricke, Martin Zimmermann, Jeanette Greiner, André Schrauder, Hansjörg Schmid, Martin Stanulla, Andishe Attarbaschi, Alfred Reiter, Georg Mann, Martin Schrappe
Journal: Blood (2009)
Final efficacy and safety results of pemetrexed (pem) continuation maintenance (mtc) therapy in the elderly from the PARAMOUNT phase III study.
Authors: Cesare Gridelli, Michael Thomas, Kumar Prabhash, Claude El Kouri, Fiona Helen Blackhall, Frederique Bustin, Belen San Antonio, Annamaria Zimmermann, Nadia Chouaki, Carla Visseren-Grul, Luis Paz-Ares
Journal: Journal of Clinical Oncology (2013)

8068 Background: The PARAMOUNT phase III trial showed that mtc pem after pem-cisplatin induction was well tolerated and effective for patients (pts) with advanced nonsquamous NSCLC. Here we present the final OS and safety data from this study in elderly (≥70 yrs) vs. non-elderly (&lt;70 yrs) pts. Methods: In this double-blind study, 539 pts with a PS of 0/1 were randomized (2:1, stratified for stage, PS and induction response) to receive mtc pem (n=359, 500 mg/m 2 , day 1, 21 day cycle) or placebo (plc) (n=180). The study was powered for PFS (previously reported) and key secondary OS. Subgroup analyses were done for pts ≥70 yrs and &lt;70 yrs. Results: Subgroups (≥70: n=92, 17%; &lt;70: n=447, 83%) had similar baseline characteristics except for PS and sex (elderly, PS 0/1: 22%/77%, M/F: 66%/34%; non-elderly, PS 0/1: 34%/65%, M/F: 56%/44%). The median ages were 73 yrs (≥70) and 60 yrs (&lt;70). The mean cycles received for pts ≥70 were 7.4 (range 1-36, dose intensity (DI) 91%) for pem and 4.5 for plc, and for pts &lt;70 were 8.0 (range 1-44, DI 94%) for pem and 5.1 for plc. The OS HRs (pem vs. plc) were 0.89 (95% CI: 0.55-1.4) for ≥70 yrs and 0.75 (95% CI: 0.60-0.95, p=0.015) for&lt;70 yrs. The median OS (95% CI) (≥70) was 13.7 mo (10.4-19.4) for pem and 12.1 mo (8.4-16.9) for plc; the median OS (95%CI) (&lt;70) was 13.9 mo (12.5-16.1) for pem and 10.8 mo (9.5-12.9) for plc. The 1 and 2 yr OS rates (95% CI) for the elderly were 60% (45-71%) and 34% (21-47%) for pem vs. 52% (36-66%) and 28% (15-43%) for plc, respectively. For non-elderly pts, the 1 and 2 yr OS rates were 58% (52-63%) and 31% (26-37%) for pem vs. 43% (35-52%) and 19% (13-27%) for plc, respectively. The Table shows a subset of drug-related AEs. Conclusions: Continuation mtc pem had comparable survival and toxicity profiles in the ≥70 and &lt;70 yrs subgroups. However, Gr 3/4 anemia and neutropenia were numerically higher for pts ≥70 yrs. Clinical trial information: NCT00789373. [Table: see text]
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of AG-519, an Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects
Authors: Ann J Barbier, Susan Bodie, Gary Connor, Elizabeth Merica, Charles Kung, Kha Le, Hua Yang, Penelope A Kosinski, Lee Silverman, Zheng (Jason) Yuan, Chris Bowden, Marvin Cohen
Journal: Blood (2016)
Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222).
Authors: Ravi Ramjeesingh, Janarthanan Kankesan, Bingshu E. Chen, Joseph L. Pater, Lei Han, Patti O'Brien, Margot J. Burnell, Lois E. Shepherd, Wendy R. Parulekar
Journal: Journal of Clinical Oncology (2015)

1033 Background: Administration of prophylactic GCSF is recommended for curative chemotherapy regimens with an estimated incidence of febrile neutropenia of ≥ 20% (Smith et al.,JCO 24:3187-3205, 2006). Clinical predictors of failure of prophylaxis are poorly understood. Methods: We retrospectively analyzed data pertaining to patients treated with dose dense EC-T chemotherapy (E: 120 mg/m2 IV Day 1 + C: 830 mg/m2 IV Day 1, q14days x 6 cycles followed by T: 175 mg/m2 IV q21days x 4 cycles) and primary prophylaxis with GCSF (5 µg/kg subcutaneously, days 2-13) on the NCIC CTG MA21 phase III study which compared 3 different anthracycline based chemotherapy regimens. An interim analysis has been published (Burnell et al., JCO, 2010). Results: 695 patients were randomized to the EC-T arm and received at least one dose of protocol therapy and primary GCSF prophylaxis. 139 (20.0%) patients experienced a febrile neutropenic event; of which 46 (33.1%) were hospitalized. There were no deaths secondary to febrile neutropenia. In a multivariate analysis, no significantly detrimental role of the covariates, including the ones listed, were identified. Conclusions: In the context of the MA.21 study, the failure rate of primary prophylaxis with GCSF therapy for prevention of febrile neutropenia in patients treated with dose dense EC-T therapy was 20% with an associated hospitalization rate of 30%. In multivariate analysis, none of the patient variables analyzed was significantly associated with failure of GCSF prophylaxis. Selected Covariates OR 95% CI P-Value Age 0.997 0.958 - 1.038 0.883 BMI 0.995 0.966 - 1.025 0.741 Diabetes 1.597 0.42 - 6.07 0.492 Liver Disease 1.335 0.149 - 11.94 0.796 Menopausal Status 1.152 0.559 - 2.215 0.672 Performance Status 1.21 0.661 - 2.214 0.537
Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis
Authors: Belal Firwana, Mohamad Bassam Sonbol, Shebli Atrash, Rahul Ravilla, Mihir Raval, Lin Hao, Yogesh Jethava, Muthu Veeraputhiran, Issam Makhoul, Appalanaidu Sasapu
Journal: Blood (2016)
A NEW PROPOSED COMPREHENSIVE CORONARY ARTERY LESION DESCRIPTION (CALD) CODE SYSTEM AND CORONARY ARTERY ANGIOGRAPHIC SEGMENTAL (CAAS) CLASSIFICATION – A MATHEMATICAL MODEL: INDIAN SOCIETY OF CARDIOLOGY (ISC) WORKING GROUP CODE FOR PHYSICIANS’ EASE
Authors: Rajendra Kumar Gokhroo
Journal: Journal of the American College of Cardiology (2017)
CD25 Expression Is Associated with Inferior Clinical Outcomes in Elderly Patients with Acute Myeloid Leukemia
Authors: Shin-ichiro Fujiwara, Kazuo Muroi, Raine Tatara, Kiyoshi Okazuka, Sato Kazuya, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Tadashi Nagai
Journal: Blood (2014)
IMPACT OF ACHIEVED BLOOD PRESSURE ON FIRST STROKE IN HYPERTENSIVE PATIENTS WITH MILD-TO-MODERATE CHRONIC KIDNEY DISEASE: A POST-HOC ANALYSIS OF THE CHINA STROKE PRIMARY PREVENTION TRIAL (CSPPT)
Authors: Youbao Li, Xianhui Qin, Xiping Xu, Yong Huo, Binyan Wang, Jianping Li
Journal: Journal of the American College of Cardiology (2017)
The Outcome of Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hemophagocytic Lymphohistiocytosis in Korea.
Authors: Jae Hee Lee, Hoi Soo Yoon, Joon Sup Song, Ho Jun Im, Hyung Nam Moon, Thad T. Ghim, Hyeong Jin Kang, Hee Young Shin, Hyo Seop Ahn, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Bin Cho, Hack Ki Kim, Dae Chul Jeong, Mee Jung Lee, Hoon Kook, Tai Ju Hwang, Jong Jin Seo
Journal: Blood (2007)
IMPAIRED CORONARY FLOW RESERVE IS ASSOCIATED WITH DIASTOLIC DYSFUNCTION AND HFPEF OUTCOMES IN PATIENTS WITHOUT OVERT CAD
Authors: Viviany R. Taqueti, John Groarke, Michael Osborne, Amil Shah, Venkatesh Murthy, Jon Hainer, Courtney Foster, Ron Blankstein, Sharmila Dorbala, Marcelo Di Carli
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF ELECTROCARDIOGRAM CHANGES ON MORTALITY IN ASYMPTOMATIC PATIENTS WITH SEPSIS AND ELEVATED TROPONIN
Authors: Hanumantha Rao Jogu, Amit Vasireddy, Muhammad I. Ahmad, Obiora Maludum, Ahmed Feroz, Mohammadtokir Mujtaba, Aysha Amjad, Reham S.M.A. Elfawal, Nishit Vaghasia, Abhishek Biswas, Simanta Dutta, Waqas Qureshi
Journal: Journal of the American College of Cardiology (2017)
ASSOCIATION BETWEEN PRESENTATION TIME AND SHORT-TERM MORTALITY IN PATIENTS WITH CARDIOGENIC SHOCK COMPLICATING ACUTE CORONARY SYNDROME: FROM JCS SHOCK REGISTRY
Authors: Taketo Sonoda, Manabu Ogita, Tetsuya Matoba, Masahiro Mohri, Nobuhiro Tanaka, Yohei Hokama, Motoki Fukutomi, Katsutaka Hashiba, Rei Fukuhara, Yasushi Ueki, Hirohide Matsuura, Satoru Suwa, Eizo Tachibana, Naohiro Yonemoto, Ken Nagao
Journal: Journal of the American College of Cardiology (2017)
Abstract 14669: Prevalence of Elevated Lp(a) Levels in 629,858 Subjects From a Referral Laboratory Population in the United States
Authors: Justin White, Steve Varvel, Sotirios Tsimikas
Journal: Circulation (2015)

Background: Elevated Lp(a) is now accepted as a causal, independent risk factor for cardiovascular disease. Data suggest that ~20% of subjects living in the Copenhagen area have elevated Lp(a) levels (&gt;50 mg/dL. Lp(a) &lt;50 mg/dL has been recommended as a desirable level, but similar large datasets in varied populations have not been available from other countries. Methods: We analyzed fasting Lp(a) in 629,858 subjects from the large referral dataset from Health Diagnostic Laboratory measured in years 2010 to 2014 to assess prevalence of elevated Lp(a). Lp(a) mass levels were measured by immunoturbidometric assay and expressed as mg/dL. Results: Median age of the subjects was 56, and 53.7% were female. Lp(a) levels were skewed rightward (Figure). The mean±SD levels were 31±38 mg/dL and median (IQR) levels were 15 (7-43) mg/dL, with range 0-571 mg/dL. Females had higher median (IQR) Lp(a) levels than males [16 (8-47) vs. 13 (6-38), p&lt;0.0001]. Lp(a) percentile levels at 75%, 80%, 90%, 95% and 99% were &gt;43 mg/dL, &gt;55 mg/dL, &gt;85 mg/dL, &gt;109 mg/dL, and &gt;169 mg/dL, respectively. Lp(a) levels &gt;30 mg/dL and &gt;50 mg/dL were present in 31.8% and 21.8% of subjects, respectively Conclusion: This is the largest database to assess the distribution of Lp(a). Lp(a) levels &gt;30 and &gt;50 mg/dL were common, constituting 31.8% and 21.8% of this referral laboratory population, and are consistent with the Copenhagen data. These data will help to define new global guidelines and therapeutic targets for new Lp(a) lowering therapies, such as antisense oligonucleotides directed to apo(a).
Protein misfolding in neurodegenerative diseases: implications and strategies
Authors: Patrick Sweeney, Hyunsun Park, Marc Baumann, John Dunlop, Judith Frydman, Ron Kopito, Alexander McCampbell, Gabrielle Leblanc, Anjli Venkateswaran, Antti Nurmi, Robert Hodgson
Journal: Translational Neurodegeneration (2017)

A hallmark of neurodegenerative proteinopathies is the formation of misfolded protein aggregates that cause cellular toxicity and contribute to cellular proteostatic collapse. Therapeutic options are currently being explored that target different steps in the production and processing of proteins implicated in neurodegenerative disease, including synthesis, chaperone-assisted folding and trafficking, and degradation via the proteasome and autophagy pathways. Other therapies, like mTOR inhibitors and activators of the heat shock response, can rebalance the entire proteostatic network. However, there are major challenges that impact the development of novel therapies, including incomplete knowledge of druggable disease targets and their mechanism of action as well as a lack of biomarkers to monitor disease progression and therapeutic response. A notable development is the creation of collaborative ecosystems that include patients, clinicians, basic and translational researchers, foundations and regulatory agencies to promote scientific rigor and clinical data to accelerate the development of therapies that prevent, reverse or delay the progression of neurodegenerative proteinopathies.
PERCUTANEOUS CORONARY INTERVENTION IS ASSOCIATED WITH DECREASED MORTALITY IN NSTEMI PATIENTS WITH ADVANCED CKD
Authors: Subir Bhatia, Shilpkumar Arora, Sravya Mallam, Kanishk Agnihotri, Parshva Patel, Nilay Patel, Apurva Badheka, Sidakpal Panaich, Abhishek Deshmukh
Journal: Journal of the American College of Cardiology (2017)
HANDS-ON TRANSRADIAL ACCESS SKILL TRAINING ON A NOVEL CADAVERIC MODEL: FINDINGS AND RECOMMENDATIONS
Authors: Ebun Ebunlomo, Luis Felipe Gomez, Nishant Patel, Joshua McKay, Ali Irshad, Thomas Loh, Rebecca Barnes, Brandi Peace, Melanie Lazarus, Alan Lumsden, C. Huie Lin
Journal: Journal of the American College of Cardiology (2017)
SCANNING THE PHENOME TO UNCOVER PLEIOTROPIC EFFECTS OF PCSK9
Authors: Maya Safarova, Erin Austin, Mariza de Andrade, Lisa Bastarache, Zhan Ye, Neil Zheng, Daniel Schaid, Marc Williams, Marylyn Ritchie, Kenneth Borthwick, Eric Larson, Aaron Scrol, Gail Jarvik, Teri Manolio, Scott Hebbring, Joshua Denny, Iftikhar Kullo
Journal: Journal of the American College of Cardiology (2017)
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.
Authors: Hendrik-Tobias Arkenau, Anas Gazzah, Ruth Plummer, Sarah Patricia Blagden, Gabriel Mak, Jean-Charles Soria, Alastair Greystoke, Ivana Rizzuto, Debra Rogan, Jolly Mazumdar, Kevin Laubscher, Kurt R Auger, Lisa S Swartz, Maria L Mattern, Noelia Nebot, Rajendra P Singh, Ronald Alan Fleming, Li Yan
Journal: Journal of Clinical Oncology (2015)

2593 Background: The focal adhesion kinase (FAK) and MAPK pathways share common upstream activators and contribute to cell proliferation, differentiation, migration and survival. Dual inhibition of both pathways with GSK2256098 and trametinib, respectively, are synergistic in cellular growth and survival assays, especially in mesothelioma cell lines. Methods: This phase Ib study (NCT01938443, funded by GSK) evaluated GSK2256098 twice daily combined with trametinib once daily in pts with advanced solid malignancies enriching for mesothelioma. The objectives were to determine the maximum-tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD). Results: As of 25 Nov 2014, 24 pts were enrolled (14 M, 10 F; median age 66 yr (range 30 to 78)). GSK2256098 at 250 or 500 mg twice-daily (BID) was orally co-administered with trametinib at 0.25, 0.375, 0.5 or 1 mg once-daily (QD) in 28-day cycles. Systemic exposure to trametinib was 2-4 X > than predicted for monotherapy causing DLTs (skin rash) and dose de-escalation. GSK2256098 PK was unchanged in the presence of trametinib. The MTD was determined to be GSK2256098 250 mg BID plus trametinib 0.5 mg QD and exposure for both agents are at concentrations that achieve antitumor activities in vitro. DLTs were observed in 6 pts (25%) at dose levels 0.5 or 1.0 mg trametinib + 500 mg GSK2256098. Median exposure was 52 days (range 17 - 181). Common adverse events (AEs), regardless of study drug relationship, were nausea (58%), diarrhea (38%), rash (33%), pruritus (33%), and vomiting (29%). Grade 3 AEs occurred in 9 individual pts (38%), and 1 (4%) Grade 4 AE occurred. One Grade 3 AE of increased CPK occurred at the MTD. Tumor biopsy PD data indicate FAK target engagement. Of 12 mesothelioma pts, 8 (67%) had stable disease lasting > 6 weeks reported as best response. Conclusions: The MTD for combined GSK2256098 and trametinib was reached, and the preliminary safety and PK/PD profile justifies further exploration. Clinical trial information: NCT01938443.
ACUTE LIMB ISCHEMIA IN A PREVIOUSLY UNDIAGNOSED CASE OF MID-VENTRICULAR NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Authors: Imo Ebong, John Rozich, Madhan Shanmugasundaram, Zachary Taylor, Rajesh Janardhanan, Divya Kapoor
Journal: Journal of the American College of Cardiology (2017)
CONTEMPORARY PATTERNS OF LIPID TESTING IN PRIMARY AND SECONDARY PREVENTION PATIENTS: INSIGHTS FROM THE PALM REGISTRY
Authors: Tracy Wang, Shuang Li, Ann Marie Navar, Veronique Roger, Jennifer Robinson, Anne Goldberg, Salim Virani, Joseph Elassal, L. Veronica Lee, Peter Wilson, Eric Peterson
Journal: Journal of the American College of Cardiology (2017)
Radiosensitization with a COX2 inhibitor with chemoradiation for head and neck cancer
Authors: P. Prellop, G. Peters, W. Carroll, L. Nabell, S. Spencer, R. Ove
Journal: Journal of Clinical Oncology (2006)

5582 Background: Cyclo-oxygenase 2 (COX2) inhibitors have shown promise as radio- and chemosensitizers. We conducted a phase IB/II study to evaluate the toxicity and efficacy of celecoxib, a selective COX2 inhibitor, administered concurrently with carboplatin, paclitaxel, and radiation for locally advanced or recurrent head and neck cancer. Methods: Patients with stage III/IV or recurrent squamous cell carcinoma of the oropharynx, oral cavity, hypopharynx, or larynx were eligible. Primary endpoints were toxicity, local control and survival. Patients were treated with weekly carboplatin (AUC = 2.0), paclitaxel (30 mg/m 2 ) and concurrent radiation (70 Gy). Celecoxib (400 mg bid) was started 1 week prior to the initiation of radiotherapy and was given for a total of 2 years. In 12/04, the study closed due to concerns of cardiotoxicity with COX-2 inhibitors. Celecoxib was discontinued in all patients. The study restarted in 5/06 with the modification that celecoxib would be given only during radiation. Results: Between 12/02 and 1/06, a total of 28 patients were enrolled: 89% were male, median age was 56.5, 3 with recurrent cancer and 25 treated definitively. Five patients have been treated on the modified study. Grade 3/4 toxicities include: mucositis (35% G3), dermatitis (18% G3; 7% G4), febrile neutropenia (21% G3; 3% G4), dysphagia (57% G3), nausea/vomiting (29% G3). Thirty percent did not complete prescribed chemotherapy due to myelosuppression. Acturarial 2 year outcomes in the 20 evaluable, definitively treated patients: 65% survival, 76% local control. Conclusions: Compared to published data using carbo/taxol and RT, an unexpectantly high incident of febrile neutropenia was observed but no increase in radiation dermatitis or mucositis. Two year survival data is comparable to published data. No significant financial relationships to disclose.
Subject Index Vol. 65, 1996
Authors: Giovanni A. Fava, Antonella Montanari, Clare Bradley, P. Bech, C. Gudex, Fuad Lechin, Bertha van der Dijs, Marcel E. Lechin, Fuad Lechin, Bertha van der Dijs, Marcel E. Lechin, Fuad Lechin, Bertha van der Dijs, Marcel E. Lechin, B. Buddeberg-Fischer, R. Bernet, J. Schmid, C. Buddeberg, Maido Uusküla, K. Staehr Johansen
Journal: Psychotherapy and Psychosomatics (1996)

medicine 49 Behcet's disease 112 Benzodiazepines 171,277 Bereavement 229 Bipolar disorder 112 Blood injury phobia 57 -pressure 129 Blue-collar worker 145 Brain-mind dichotomy 229 Breast cancer 102 Bulimia 272 -nervosa 29, 158 Bunting mouth syndrome 163
REAL-WORLD COMPARISON OF MAJOR BLEEDING AND ASSOCIATED COSTS AMONG ORAL ANTICOAGULANT-NAÏVE NON-VALVULAR ATRIAL FIBRILLATION PATIENTS INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARIN IN THE US MEDICARE POPULATION
Authors: Alpesh Amin, Allison Keshishian, Jeffrey Trocio, Hannah Le, Oluwaseyi Dina, Zhang Qisu, Onur Baser, Lien Vo
Journal: Journal of the American College of Cardiology (2017)
THE EFFECT OF MIXED AORTIC VALVE DISEASE IN CLINICAL OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Konstantinos Stathogiannis, Konstantinos Toutouzas, Maria Drakopoulou, Archontoula Michelongona, Andreas Synetos, George Latsios, George Trantalis, Odysseas Kaitozis, Constantina Aggeli, Eleftherios Tsiamis, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2017)
CHRONIC STENT RECOIL DURING FOLLOW-UP IN SEVERELY CALCIFIED CORONARY ARTERY LESIONS: AN OPTICAL COHERENCE TOMOGRAPHY STUDY
Authors: Kisaki Amemiya, Akiko Maehara, Myong Hwa Yamamoto, Yuji Oyama, Wataru Igawa Igawa, Morio Ono, Kido Takehiko, Seitarou Ebara, Toshitaka Okabe, Kennosuke Yamashita, Shigeo Saito, Koichi Hoshimoto, Tadayuki Yakushiji, Naoei Isomura, Hiroshi Araki, Gary Mintz, Masahiko Ochiai
Journal: Journal of the American College of Cardiology (2017)